| 1. |
- Belin, Matts-Åke, et al.
(författare)
-
Speed Cameras in Sweden and Victoria, Australia : A case study
- 2010
-
Ingår i: Accident Analysis and Prevention. - : Elsevier BV. - 0001-4575 .- 1879-2057. ; 42:6, s. 2165-2170
-
Tidskriftsartikel (refereegranskat)abstract
- In this article, the ideas behind two different speed camera systems in Australia, Victoria, and Sweden are explored and compared. The study shows that even if the both systems technically have the same aim – to reduce speeding – the ideas of how that should be achieved differ substantially. The approach adopted in Victoria is based on the concept that speeding is a deliberate offence in which a rational individual wants to drive as fast as possible and is prepared to calculate the costs and benefits of his behaviour. Therefore, the underlying aim of the intervention is to increase the perceived cost of committing an offence whilst at the same time decrease the perceived benefits, so that the former outweigh the latter. The Swedish approach, on the other hand, appears to be based on a belief that road safety is an important priority for the road users and one of the reasons to why road users drive too fast is lack of information and social support. In order to evaluate road safety interventions and how their effects are created together with the ambition to transfer technology, there is a need for a comprehensive understanding of the systems and their modi operandi in their specific contexts. This study has shown that there are major differences between the ideas behind the two speed camera programs in Victoria, Australia and Sweden and that these ideas have an impact on the actual design of the different systems and how these are intended to create road safety effects.
|
|
| 2. |
- Einarsson, Jon Thorkell, et al.
(författare)
-
Rituximab in clinical practice : dosage, drug adherence, Ig levels, infections, and drug antibodies
- 2017
-
Ingår i: Clinical Rheumatology. - : Springer Science and Business Media LLC. - 0770-3198 .- 1434-9949. ; 36:12, s. 2743-2750
-
Tidskriftsartikel (refereegranskat)abstract
- The objective of this study is to explore the following: (1) the impact of two different initial doses and cumulative 2-year dose of rituximab (RTX) on drug adherence and predictors of adherence to treatment in rheumatoid arthritis (RA) patients in an observational clinical setting, (2) immunoglobulin levels (IgG/IgM/IgA) during repeated treatment and their relation to infections, and (3) development of anti-rituximab antibodies (ADA). All RA patients receiving RTX from January 2003 to April 2012 at the department were included. The initiating doses were 500 or 1000 mg intravenously days 1 and 15. Drug adherence was estimated using life-table. Baseline predictors of adherence to treatment were analyzed using Cox regression model. Levels of immunoglobulins were measured at treatment initiation and before retreatment. Serum levels of RTX and ADA were measured in 96 patients at 6 months using ELISA. One hundred fifty-three patients were included. Seventy-four (48%) started treatment with 500 and 79 (52%) with 1000 mg. No difference in drug adherence was seen between the different initial or cumulative RTX doses. Methotrexate (MTX) use and low DAS28 at baseline predicted better drug adherence. Ig levels decreased with repeated treatments but low levels were not associated with infections. 11/96 patients had developed ADA at 6 months. Long-term adherence to RTX in RA patient was not influenced by starting- or cumulative 2-year doses. MTX use and low DAS28 at baseline was positively associated with drug adherence. Decreasing Ig levels during treatment were not associated with risk of infections. Development of ADA may influence treatment efficacy and tolerability.
|
|
| 3. |
- Tjörnstrand, Axel, et al.
(författare)
-
The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011
- 2014
-
Ingår i: European Journal of Endocrinology. - 0804-4643 .- 1479-683X. ; 171:4, s. 519-526
-
Tidskriftsartikel (refereegranskat)abstract
- © 2014 European Society of Endocrinology. Objective: The number of studies on the incidence of pituitary adenomas (PAs) is limited. The aim of this study was to evaluate the standardised incidence rate (SIR) of PAs in western Sweden.Design, subjects and methods: Data from adult patients diagnosed with PAs in 2001-2011, living in the Vä stra Götaland County, were collected from the Swedish Pituitary Registry (SPR). In addition, medical records on all patients diagnosed with PAs at the six hospitals in the region were reviewed. In total, 592 patients were included in the study.Age-SIR, given as rate/100 000 inhabitants (95% CI), was calculated using the WHO 2000 standard population as a reference.Results: The total SIRfor PAswas 3.9/100 000 (3.6-4.3); 3.3/100 000 (2.9-3.7) formen and 4.7/100 000 (4.1-5.3) forwomen. Inmen, SIR increasedwith age, while inwomen SIR peaked at 25-34 years, mainly due to prolactinomas. Non-functioning PA (NFPA)was the most common PA (54%, 1.8/100 000 (1.6-2.0)) followed by prolactinomas (32%, 1.6/100 000 (1.3-1.9)), acromegaly (9%, 0.35/100 000 (0.25-0.45)), Cushing'sdisease (4%, 0.18/100 000 (0.11-0.25)) andTSH-producingPA(0.7%, 0.03/100 000 (0.00-0.05)). The proportion of macroadenomas for NFPA was 82%, prolactinomas 37%, GH-producing PA 77%, ACTH-producing PA 28% and TSH-producing PA 100%. The lifetime risk for PAs was 0.27% (0.24-0.31) in men and 0.29% (0.26-0.33) in women.Conclusion: This study provides a reliable estimate on the overall incidence of PAs and confirms an increased incidence of PAs compared with studies conducted in the pre-magnetic resonance imaging era. The lower proportion of prolactinomas compared with previous studies is probably explained by the different criteria used.
|
|
